This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Ferring B.v., Institut Pasteur. Active years: 2019-2025.
Location History:
- Ollon, CH (2019)
- Saint-Prex, CH (2021 - 2024)
Company Filing History:
3 out of 209 
3 out of 897 
Years Active: 2019-2025
Title: The Innovative Contributions of Pascal Danglas
Introduction
Pascal Danglas is a notable inventor based in Saint-Prex, Switzerland. He has made significant contributions to the field of bacteriophage therapy, focusing on innovative treatments for inflammatory bowel disease. With a total of 4 patents to his name, Danglas continues to push the boundaries of medical science.
Latest Patents
One of his latest patents involves a pharmaceutical composition that includes at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive strain. This invention aims to provide a method for treating inflammatory bowel disease by administering the bacteriophage strain to affected subjects. Additionally, the patent introduces new bacteriophage strains that can be utilized in this therapeutic approach.
Career Highlights
Throughout his career, Pascal Danglas has worked with reputable organizations such as Ferring B.V. and Institut Pasteur. His experience in these institutions has allowed him to develop and refine his innovative ideas in bacteriophage therapy.
Collaborations
Danglas has collaborated with esteemed colleagues, including Laurent Debarbieux and Michael Reidy. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Pascal Danglas is a pioneering inventor whose work in bacteriophage therapy is making a significant impact in the treatment of inflammatory bowel disease. His innovative patents and collaborations highlight his commitment to advancing medical science.